Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-cell-replete peripheral blood stem cells refers to **allogeneic or autologous peripheral blood stem cell grafts that have not undergone ex vivo T-cell depletion**. They are collected from the donor's blood after mobilization (often with granulocyte colony-stimulating factor, G-CSF) and contain a full complement of T-cells along with hematopoietic stem cells. This product is used in **hematopoietic stem cell transplantation (HSCT)**, particularly in settings where a rapid immune reconstitution is desired, such as for patients with high-risk or refractory hematologic malignancies (e.g., acute leukemias, lymphomas). By retaining T-cells, these grafts can promote faster immune recovery but may also increase the risk of graft-versus-host disease (GvHD); consequently, intensive in vivo immunosuppressive prophylaxis (e.g., post-transplantation cyclophosphamide or anti-thymocyte globulin) is used to mitigate this risk. Clinical protocols vary based on donor type (matched sibling, matched unrelated, or haploidentical), donor-recipient compatibility, and disease indication[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on T-cell-replete peripheral blood stem cells.